Intercept Pharmaceuticals, Inc. (ICPT) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 New York City, NY, 美国. 现任CEO为 Jerome B. Durso.
ICPT 拥有 IPO日期为 2012-10-11, 341 名全职员工, 在 NASDAQ Global Select, 市值为 $794.69M.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
